Drug Research
Eisai’s DAYVIGO gets approval in Japan to treat insomnia
Eisai Co., Ltd. announced that it has obtained the manufacturing and marketing approval in Japan for its in-house discovered orexin receptor antagonist DAYVIGO (2.5mg, 5mg, and 10mg tablets, lemborexant) for treatment of insomnia.
DAYVIGO is a dual orexin receptor antagonist...
Clinical Trials
First-of-its-Kind Bio-Artificial Pancreas on Track for Type-I Diabetes Cure
Imagine a world where those living with Type 1 Diabetes, a chronic illness affecting more than 60 million adults globally, no longer had to deal with regular blood glucose monitoring, daily insulin injections or life-threatening nighttime hypoglycemic events, but...
Drug Research
Eisai Commences Joint Research and Development of Cancer Gene Panel Test With Personal Genome Diagnostics Inc
Eisai Co., Ltd. announced that it has entered into a joint research and development agreement with Personal Genome Diagnostics Inc. for the cancer genetics panel test, and it has initiated the research.
In this joint research and development, Eisai and...
Drug Research
Medigene, IRICoR and Universite de Montreal sign collaboration and exclusive licensing option on novel cancer antigens
Medigene AG , a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies, announces that it has entered into a research collaboration on novel cancer antigens for highly specific immunotherapies with the Universite de Montreal (UdeM) and...
Press Releases
Signant Health Enhances Audit Trail Reporting Capabilities in TrialMax to Improve eCOA Data Integrity Monitoring
Signant Health has announced new audit trail reviewing and reporting functionality for its electronic clinical outcome assessment (eCOA) and remote sensor platform, TrialMax®. This new functionality enables authorized personnel to simply and quickly access and explore key audit trail...
Clinical Trials
SAGA Diagnostics Extends its Collaboration with Servier to Use Ultrasensitive SAGAsafe Technology in Cancer Clinical Trials
SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, announces it has entered service agreements with the international pharmaceutical company Servier, based in Paris, France.
“These deals...
Clinical Trials
PHARMASEAL Celebrates A Year of Significant Success as it Prepares for Exciting Program of Industry Conferences in 2020
PHARMASEAL, a new provider of clinical trial management (CTMS) and governance solutions to enter the market, is celebrating a year of significant success, with 2019 marking several important milestones for the company. This includes winning Start-Up of the Year...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read